Confirmed
One controlled phase 3 trial met its main goal, and eculizumab is approved for this use.
Eculizumab: prevent attacks in NMOSD
NMOSD · Complement inhibition
Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Trials
- 6
- Running now
- 2
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 143
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 5
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2014 · Placebo-controlled · MSFT-NCT01892345
Adjudicated relapses occurred in 3 of 96 patients (3%) in the eculizumab group and 20 of 47 (43%) in the placebo group (hazard ratio, 0.06; 95% confidence interval [CI], 0.02 to 0.20; P<0.001).
Read by software from the paper's abstract
Other linked trials: 5
These linked trials do not set the status.
- BEST-NMOSDOngoing
Phase 4 · 2026 · Not randomised
- ECU-NMO-304Ongoing
Phase 3 · 2025 · Not randomised
Phase 3 · 2015 · Not randomised
- A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum DisorderStopped, other reason
Phase 2/3 · 2020 · Not randomised
Phase 1/2 · 2009 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Status changed from Being tested to Confirmed
- 2026-10-27First listed as Being tested
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error